Home All Products GLP-1 SV
GLP-1 SV
GLP-1 SV

GLP-1 SV

Survodutide is a synthetic 29-amino-acid peptide engineered as a dual agonist of the GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR).

Modified with a C18 fatty diacid chain to enable albumin binding, it exhibits an extended half-life of ~109–115 hours, supporting once-weekly subcutaneous administration.

The molecule demonstrates preferential GLP-1R activation over GCGR (~8:1 ratio), designed to maximize metabolic benefits while minimizing glucagon-related tolerability issues.

(Investigational compound; not FDA-approved.)

Mechanism of Action

  • GLP-1R Activation
    • Enhances glucose-dependent insulin secretion
    • Suppresses post-prandial glucagon
    • Delays gastric emptying
    • Reduces appetite via central hypothalamic pathways
  • GCGR Activation
    • Increases energy expenditure via hepatic fatty-acid oxidation
    • Promotes thermogenesis and lipolysis
    • Reduces hepatic biomarkers (FGF21, NNMT)
  • Dual Pathway Synergy
    • Appetite suppression + increased energy expenditure for enhanced metabolic effect profiles

Clinical References

  1. Rosenstock, J., et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity. The Lancet Diabetes & Endocrinology, 12(3), 161–173. DOI: 10.1016/S2213-8587(23)00356-X
  2. Frías, J.P., et al. (2024). Biomarker-guided approach to select survodutide for clinical development. Diabetes, Obesity and Metabolism, 26(7), 2731–2741. DOI: 10.1111/dom.15619
  3. Tsoukas, M.A., et al. (2024). Survodutide: Novel mechanism of action for obesity and type 2 diabetes. Annals of Medicine and Surgery, 86(5), 2756–2763. DOI: 10.1097/MS9.0000000000001898
  4. le Roux, C.W., et al. (2024). Rationale and design of Phase 3 trials (SYNCHRONIZE-1 and -2). Obesity, 33(2), 278–289. DOI: 10.1002/oby.24150
  5. Rosenstock, J., et al. (2023). Weekly survodutide improves glycemic control in T2DM: Phase 2 trial. The Lancet Diabetes & Endocrinology, 11(11), 800–811. DOI: 10.1016/S2213-8587(23)00244-9

*Based on Phase 1–2 trial data; not clinical treatment claims.

  • Weight Loss: Up to 14.9% mean reduction;
~40% of subjects achieved >20% reduction in Phase 2 research
  • Dual Pathway Metabolism: Combines GLP-1–mediated appetite reduction with glucagon-mediated energy expenditure
  • Glycemic Control: HbA1c reduction of ~1.5% in T2DM subjects—similar to semaglutide, with added weight-loss effects
  • Cardiometabolic Health: Lowered blood pressure, triglycerides, and multiple cardiovascular risk markers
  • Energy Expenditure: Increased basal metabolic rate and enhanced fatty-acid oxidation
  • Lean Mass Preservation: Muscle mass maintained despite significant weight reduction
  • Liver Health: Reduced hepatic lipid content in MASH/NAFLD models
  • Dosing Convenience: Once-weekly administration due to long half-life
  • Clinical Development: Progressing through Phase 3 trials evaluating safety and metabolic outcomes

$210.00

Per Unit
In stock

Free Shipping on All Orders $1000+